Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garetosmab in Japanese adults with FOP
NCT04577820Phase 3Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of garetosmab in fibrodysplasia ossificans progressiva (FOP), sponsored by Regeneron Pharmaceuticals. Planned start Oct 2021; status: withdrawn.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT04577820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577820.